Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

Lars Pål Hasvold,Johan Bodegard,Marcus Thuresson,Jan Stålhammar,Niklas Hammar,Johan Sundström,David Russell,Sverre E. Kjeldsen

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

2014

Lars Pål Hasvold
Johan Bodegard
Marcus Thuresson
Jan Stålhammar
Niklas Hammar
Johan Sundström
David Russell
Sverre E. Kjeldsen

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

Keywords:

Endocrinology
Angiotensin II Type 1 Receptor Blockers
Primary health care
Internal medicine
Diabetes mellitus
Enalapril
Angiotensin-converting enzyme
Blood pressure
Angiotensin receptor
Pharmacology
Medicine
Enzyme inhibitor
Type 2 diabetes
Lower risk
Hazard ratio
Candesartan

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations